MRI Assessment of Leukemia Response to Therapy
The purpose of this study is to investigate if a type of magnetic resonance imaging (MRI) scan of the bone marrow before the start of standard chemotherapy can predict complete remission of leukemia patients after the therapy. This type of MRI scan, called dynamic contrast-enhanced MRI (DCE-MRI), measures bone marrow blood flow. For those patients who do not achieve complete remission status after initial therapy and will be treated with additional therapy, the investigators are also interested in determining if the second MRI exam before the additional therapy can predict complete remission. If successfully tested, the MRI exam may be used in the future to help with early identification of patients who are unlikely to respond to standard chemotherapy. This will allow for a personalized therapeutic plan to be developed for these patients at an early stage and prevent them from being exposed to toxic and ineffective therapies.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Quantitative DCE-MRI as a Predictor of Therapeutic Response in Acute Leukemia|
- Shutter-Speed Model [ Time Frame: Up to 1 year ] [ Designated as safety issue: No ]To explore if Shutter-Speed Model (SSM) dynamic contrast-enhanced MRI (DCE-MRI)of the bone marrow (BM) can predict complete remission (CR) in newly diagnosed or relapsed acute myelogenous leukemia (AML)patients.
- Pilot Data [ Time Frame: Up to 1 year ] [ Designated as safety issue: No ]To collect pilot data in SSM DCE-MRI assessment of AML response to therapy for the conduct of future studies.
- Complete Response [ Time Frame: Up to 1 year ] [ Designated as safety issue: No ]To explore whether SSM DCE-MRI differs in predicting complete response (CR) for the newly diagnosed AML patients and for the relapsed AML patients.
- Second SSM DCE-MRI [ Time Frame: Up to 1 year ] [ Designated as safety issue: No ]To explore if the second SSM DCE-MRI and/or changes between the first and second imaging studies can predict CR in the non-CR group who undergo an additional therapy.
- DCE-MRI Biomarkers [ Time Frame: Up to 1 year ] [ Designated as safety issue: No ]To compare/correlate/combine DCE-MRI bio-markers with micro-vascular density (MVD) and proangiogenic cytokine profiles for the purpose of predicting response of AML patients to therapy.
|Study Start Date:||April 2012|
|Estimated Primary Completion Date:||May 2013 (Final data collection date for primary outcome measure)|
Acute Myelogenous Leukemia (AML)
Patients who have been diagnosed with AML
Device: 3T Siemens TIM Trio whole-body system
Each MR scanning session will include the pre-contrast multi-slice T2-weighted MRI with fat-saturation and T1-weighted MRI which are regularly acquired in clinical protocols. Following these acquisitions, high-spatial and temporal-resolution DCE-MRI will be performed. The total duration of a research MR session is expected to be less than 45 min.
Other Name: Magnetic Resonance Imaging (MRI)
|Contact: Aneela Afzalfirstname.lastname@example.org|
|United States, Oregon|
|Oregon Health and Science University||Recruiting|
|Portland, Oregon, United States, 97239|
|Contact: Aneela Afzal email@example.com|
|Principal Investigator: Wei Huang, PhD|
|Principal Investigator:||Wei Huang, PhD||OHSU Knight Cancer Institute|